ArticleMaterials (Basel, Switzerland)2026
Physicochemical Characterization of the Salmon Bone Hydroxyapatite and Collagen Mixture.
Article in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and characterize a particulate biomaterial composed of hydroxyapatite derived from salmon bone and bovine type I collagen (HAPS/COL), and to evaluate whether different inorganic-organic ratios influence its physicochemical properties. MATERIALS &
methodsBiomaterials were produced using three HAPS/COL proportions (70/30, 80/20, and 90/10). Physicochemical characterization included pycnometry, X-ray diffraction (XRD), thermogravimetric analysis (TGA), and scanning electron microscopy with energy-dispersive X-ray spectroscopy (SEM-EDX).
resultsPycnometry showed densities close to that of pure hydroxyapatite, with only slight decreases attributable to collagen content. SEM-EDX images showed comparable surface morphologies characterized by hydroxyapatite particulates surrounded by collagen fibers. Ca/P ratios were slightly higher than the stoichiometric value of hydroxyapatite. XRD confirmed hydroxyapatite as the dominant crystalline phase across all formulations, with no evidence of phase alteration. TGA revealed mass losses of 2.75%, 1.90%, and 1.60% for the 70/30, 80/20, and 90/10 mixtures, respectively, with consistent mass loss-to-collagen ratios of approximately 0.09 for the 70/30 and 80/20 formulations, confirming proportional organic phase degradation.
conclusionsThe three HAPS/COL ratios produced biomaterials with highly similar physicochemical profiles, indicating that within the tested range, the proportion of hydroxyapatite and collagen does not substantially alter material structure, composition, or thermal behavior. These findings confirm the successful manufacture of a stable HAPS/COL blend, allowing the use of efficient quantities of collagen, thus minimizing the costs associated with its purchase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.